Document:

Bupropion Hydrochloride Supply Agreement

 Exhibit 10.23 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION 
 BUPROPION HYDROCHLORIDE SUPPLY AGREEMENT 
 This Bupropion Hydrochloride Supply Agreement (this “Agreement”) is made as of this day of November 24, 2009
(the “Effective Date”) by and among OREXIGEN THERAPEUTICS, INC. (“OREXIGEN”), a Delaware corporation located at 3344 N. Torrey Pines Court, Suite 200, La Jolla, CA 92037, and CHEMI S.p.A. (“CHEMI”),
a corporation of Italy located at via dei Lavoratori, 54 -20092, Cinisello Balsamo (Milan). 
 WHEREAS, CHEMI is the manufacturer of
Bupropion Hydrochloride and is contractually responsible for Bupropion Hydrochloride and whereby CHEMI wishes to sell and manufacture Bupropion Hydrochloride to OREXIGEN on the terms described herein; and 
 WHEREAS, OREXIGEN desires a supply of commercial quantities of Bupropion Hydrochloride on the terms described herein. 
 NOW, THEREFORE, in consideration of the mutual covenants set forth herein, CHEMI and OREXIGEN (each, a “Party” and, collectively, the
“Parties”) agree as follows. 
  

	1.	SCOPE OF AGREEMENT 

  

	1.1.	This Agreement shall apply to all purchases of Bupropion Hydrochloride by OREXIGEN from CHEMI during the term of this Agreement. The premises and the Schedules and
Appendix attached hereto constitute an integrant and substantial part of this Agreement. 

  

	1.2.	This Agreement does not constitute a purchase order. Purchases under this Agreement shall be made only with purchase orders issued by OREXIGEN to CHEMI (each, a
“Purchase Order”). Each Purchase Order shall set forth the information required by Section 3.3 and shall be in the form attached hereto as Appendix A. All terms and conditions of the Purchase Orders shall apply, provided
that in the event of a conflict or inconsistency between the terms of any Purchase Order, order acknowledgement, invoice, shipping terms, packaging slip or other documentation, and the terms of this Agreement, the terms of this Agreement shall
control and prevail and such additional or inconsistent terms are hereby expressly rejected, unless such documentation specifically states that it overrides conflicting terms of this Agreement and is signed by each of the Parties.

  

	1.3.	All Bupropion Hydrochloride sold by CHEMI to OREXIGEN will be manufactured by CHEMI in accordance with the terms of this Agreement. 

  

	2.	MANUFACTURING; SPECIFICATIONS 

  

	2.1.	 CHEMI shall supply the Bupropion Hydrochloride to OREXIGEN in accordance with (a) the specifications set forth on Schedule A attached
hereto, and (b) the specifications, methods, processes and procedures, including site of manufacture, set forth in CHEMI’s drug master file (“DMF”) for Bupropion Hydrochloride filed with the U.S. Food and Drug
Administration (“FDA”) pursuant to Section 2.3 (both (a) and (b), including any

	 	 
modifications approved in accordance with Section 2.2 collectively, the “Specifications”). If CHEMI wishes to make any change to the Specifications (including, but not
limited to, any change that could affect the purity, potency, identity and/or physical properties of the Bupropion Hydrochloride or the site of its manufacture), it shall notify OREXIGEN in writing in advance thereof and comply with the requirements
of Section 2.2 prior to implementing such change. Such notification shall describe the proposed change in sufficient detail, so as to permit OREXIGEN to understand the reasons for the proposed change and evaluate the impact of such change on
its development plans, its plans to seek regulatory approval and its commercialization plans with respect to oral formulations containing Bupropion Hydrochloride (the “Finished Products”). OREXIGEN may request from time to time that
CHEMI implement voluntary changes to the Specifications upon written request to CHEMI. CHEMI shall use commercially reasonably efforts to implement such request from OREXIGEN, which if carried out shall be at OREXIGEN’s expense. In the event
that a voluntary change to the Specifications is to be implemented, CHEMI shall perform, at OREXIGEN’s expense, all analytical or experimental work in connection with making any such changes, but OREXIGEN shall be responsible, at its expense,
for filing all changes proposed by OREXIGEN in connection with any regulatory approval, and for seeking approval of any such change required by each applicable Regulatory Agency (as defined in Section 2.2). 

  

	2.2.	Without limiting the generality of the foregoing provisions, CHEMI shall not change the Specifications unless [* * *], each having jurisdiction over Bupropion
Hydrochloride, the Finished Products or OREXIGEN’s marketing of Finished Products (each a “Regulatory Agency”). If any change to the Specifications requires the approval of a Regulatory Agency, such change [* * *]. To
the extent [* * *]. For the avoidance of doubt, CHEMI shall not supply to OREXIGEN hereunder, and OREXIGEN shall have no obligation to accept, any Bupropion Hydrochloride from CHEMI manufactured in contravention of this Section 2.2.

  

	2.3.	CHEMI will take commercially reasonable steps necessary to enable OREXIGEN to secure from the relevant Regulatory Agencies approval of CHEMI as a source of supply of
Bupropion Hydrochloride for OREXIGEN’s Finished Products to be marketed anywhere in the world. Without limiting the generality of the foregoing, CHEMI will supply to OREXIGEN sufficient quantities of Bupropion Hydrochloride to enable OREXIGEN
to support the filing of one or more New Drug Applications (the “NDA”) (or Abbreviated New Drug Application (“ANDA”), if applicable), together with all amendments and supplements thereto, referencing CHEMI as its
supplier of Bupropion Hydrochloride for its initial Finished Product candidate. CHEMI will be responsible for procuring and maintaining all regulatory filings and any other compliance efforts, including without limitation, the DMF, related to
Bupropion Hydrochloride that are required in order to obtain approval from the FDA of OREXIGEN’s NDAs (or ANDAs, if applicable) referencing Bupropion Hydrochloride and equivalent approvals from Regulatory Agencies in other jurisdictions, at no
additional cost to OREXIGEN. CHEMI has filed the DMF with the FDA and has provided the DMF’s reference number in writing to OREXIGEN at least [* * *] ([* * *]) days prior to Orexigen’s filing of an NDA (or ANDA, if
applicable). OREXIGEN shall have the right to reference the DMF in its 

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
NDAs (or ANDAs, if applicable) and equivalent approvals from Regulatory Agencies in jurisdictions outside the United States, and the right to access the open part of the DMF.

  

	2.4.	CHEMI shall test, or have tested, each lot of Bupropion Hydrochloride shipped to OREXIGEN using the analytical testing methodologies which are set forth in the
Specifications in order to assure the conformity of each lot of Bupropion Hydrochloride supplied hereunder to the Specifications and all Applicable Laws (as defined in Section 8.1.1). With each shipment of Bupropion Hydrochloride, CHEMI shall
deliver to OREXIGEN certificates of analysis and compliance from CHEMI (a) stating that the Bupropion Hydrochloride being shipped has been tested and does conform to the Specifications, (b) setting forth in detail the testing methodology
employed by CHEMI in making the foregoing determination and the results generated by such tests, and (c) confirming compliance with the current good manufacturing practices (“cGMP”) required by the FDA, and other relevant
Regulatory Agencies in those jurisdictions of which OREXIGEN has given CHEMI notice, with respect to the manufacture and testing of Bupropion Hydrochloride for use as an active pharmaceutical ingredient in the Finished Products and subsequent sale
in such jurisdictions. 

  

	3.	FORECASTS; FIRM COMMITMENT; PURCHASE ORDERS 

  

	3.1.	In order to assist CHEMI in planning the production runs for Bupropion Hydrochloride, beginning at least [* * *] ([* * *]) [* * *] prior
to OREXIGEN’s anticipated Commercial Launch (as defined in Section 3.2), OREXIGEN shall use its commercially reasonable efforts to provide to CHEMI, prior to the beginning of each calendar quarter, a twelve (12) month rolling forecast
of the quantities of Bupropion Hydrochloride required by OREXIGEN, by month, for the following twelve (12) month period (the “Rolling Forecast”). OREXIGEN may, at its discretion, update such Rolling Forecast more frequently.
The first three (3) months of each Rolling Forecast shall constitute a binding order on CHEMI and OREXIGEN for the quantities of Bupropion Hydrochloride specified therein (“Firm Commitment”), and the following [* * *]
([* * *]) months of the Rolling Forecast shall be non-binding estimates and shall be used by CHEMI for planning purposes only. CHEMI shall be obligated to supply no less than [* * *] percent ([* * *]%) of the quantity
of Bupropion Hydrochloride ordered by OREXIGEN pursuant to any Purchase Order which complies with Section 3.3. Further, CHEMI agrees to use commercially reasonable efforts to deliver any quantities of Bupropion Hydrochloride ordered by OREXIGEN
which exceed OREXIGEN’s Firm Commitment by not more than [* * *] percent ([* * *]%) or for which a delivery date of less than [* * *] ([* * *]) days from the date of such Purchase Order is requested by
OREXIGEN. 

  

	3.2.	 After the Finished Products have received approval for marketing from a Regulatory Agency (the date of such approval hereinafter referred to as the
“Qualification Date”) and have been made generally commercially available (hereinafter “Commercial Launch”), CHEMI shall, within [* * *] ([* * *]) business days after OREXIGEN has provided
its quarterly forecast, notify OREXIGEN in writing of any prospective problems CHEMI might have with respect to supplying OREXIGEN’s forecasted order quantities. Upon receipt of such notice, the Parties shall promptly discuss the inability to
supply the amounts forecasted by OREXIGEN and work in good faith to agree upon

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
revised forecast amounts. Failing agreement, OREXIGEN’s last submitted forecast shall be deemed to be the new quarterly forecast. The foregoing notice and discussion requirements of this
Section 3.2 shall not operate to relieve CHEMI of its obligations pursuant to any Firm Commitment Purchase Order (as defined in Section 3.3), or affect OREXIGEN’s right to pursue any remedies that may be available to it.

  

	3.3.	Prior to the beginning of each calendar quarter, OREXIGEN shall submit a binding, non-cancelable Purchase Order for the most recent Firm Commitment portion of the
Rolling Forecast for such calendar quarter (“Firm Commitment Purchase Order”). Each Purchase Order shall specify the quantity of Bupropion Hydrochloride ordered, the total Price (as defined in Section 5.2) for such quantities
of Bupropion Hydrochloride calculated in accordance with Section 5 hereof, and the required delivery date and destination, consistent with the terms of this Agreement. OREXIGEN shall submit each Purchase Order to CHEMI at least
[* * *] ([* * *]) days in advance of the delivery date requested in the Purchase Order. Within [* * *] ([* * *]) business days after the date that a Purchase Order is submitted, CHEMI shall acknowledge receipt
of OREXIGEN’s Purchase Order and confirm that the amounts of Bupropion Hydrochloride ordered in the Purchase Order will be timely supplied. For the avoidance of doubt, CHEMI shall be obligated to accept any such Purchase Order which complies
with this Section 3.3. Notwithstanding the foregoing, any failure by CHEMI to respond to a Purchase Order within such [* * *] ([* * *]) day period shall be deemed acceptance of such Purchase Order. 

 

	3.4.	CHEMI agrees to retain a safety stock of Bupropion Hydrochloride to be used for sale by OREXIGEN based on the average monthly quantities in the Rolling Forecast. CHEMI
will promptly notify OREXIGEN if CHEMI’s manufacturing capacity will be insufficient to fill a Purchase Order submitted by OREXIGEN. 

  

	3.5.	During any period during this Agreement in which CHEMI, for any reason, including, without limitation, a force majeure as provided in Section 13.1, fails to
deliver the requisite quantities of Bupropion Hydrochloride included within any Firm Commitment Purchase Order, within [* * *] ([* * *]) days after the date of delivery confirmed in writing by CHEMI or if CHEMI otherwise
anticipates or notifies OREXIGEN that it will be unable to make delivery of all or a portion of the ordered Bupropion Hydrochloride within [* * *] ([* * *]) days after the confirmed date of delivery, then OREXIGEN may refuse such
late shipment of Bupropion Hydrochloride from CHEMI and purchase such quantities elsewhere. OREXIGEN shall have no further obligations to purchase the undelivered Bupropion Hydrochloride ordered from CHEMI pursuant to a Firm Commitment Purchase
Order. 

  

	4.	DELIVERY 

  

	4.1.	Each Purchase Order shall specify the quantity of Bupropion Hydrochloride ordered and the required delivery date and destination, consistent with the terms of this
Agreement. 

  

	4.2.	 Freight and other delivery terms shall be as set forth in Schedule B. Title of the Bupropion Hydrochloride shall pass from CHEMI to
OREXIGEN upon receipt by

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
OREXIGEN or its designated agents of such product at the location specified in the Purchase Order. 

  

	4.3.	CHEMI shall deliver the complete order amounts on the delivery date specified in the Purchase Order. CHEMI shall be responsible for coordinating the export of the
Bupropion Hydrochloride to the United States and to OREXIGEN’s designated Custom Agent in a timely manner and in compliance with the Specifications and all Applicable Laws. CHEMI shall notify OREXIGEN of the expected delivery date of the order
to enable receipt to be coordinated. 

  

	4.4.	Bupropion Hydrochloride shall be delivered to OREXIGEN’s pursuant to the terms set forth in Schedule B in CHEMI’s normal packaging and documentation for
Bupropion Hydrochloride, including, without limitation, any such procedures as reflected in CHEMI’s DMF, provided that such packaging and documentation shall meet the customs and regulatory requirements within the United States and as
applicable, to the location of OREXIGEN’s designated facility for delivery. Each shipment shall include certificates of analysis and compliance, which include, without limitation, a statement of compliance with cGMP, and such other
documentation and information as may be necessary or desirable for complying with import, export and customs laws, regulations and requirements as applicable. 

  

	5.	PRICE AND PAYMENT 

  

	5.1.	The price for the Bupropion Hydrochloride to be purchased by OREXIGEN hereunder is set forth in Schedule B, as adjusted in accordance with this
Section 5 (the “Price”). 

  

	5.2.	The Price shall remain fixed for the first [* * *] ([* * *]) months of the Agreement, and thereafter shall be adjusted in accordance with this
Section 5.2 on [* * *] to take effect for orders to be delivered after such applicable [* * *]. The Price shall be adjusted based on the [* * *] in [* * *]. The price [* * *] will be calculated
[* * *] months prior to the [* * *] with notification of said price [* * *] is to be made to OREXIGEN by CHEMI no later than [* * *] months prior to each [* * *] for implementation on the Effective
Date. 

  

	5.3.	 CHEMI and OREXIGEN, as applicable, shall be entitled to adjust the Price at any time during the term of this Agreement (to take effect for Purchase
Orders accepted after the date of such adjustment) by giving [* * *] ([* * *]) days prior written notice to the other Party solely to take into account any documented and verifiable increases or decreases in the [* * *]
resulting from (i) [* * *] (“[* * *] Price Change”), or (ii) changes in [* * *] or [* * *] (other than as a result of [* * *]) or any changes to [* * *]
(“[* * *] Price Change”). In the event of (i) a [* * *] Price Change, CHEMI and OREXIGEN shall negotiate in good faith to adjust the Price based on the changes to the [* * *], and (ii) a
[* * *] Price Change, the Price shall be increased by an amount equal to [* * *] percent ([* * *]%) of [* * *] Price Change, provided that in either case, if the applicable change results in an increase in the
Price payable by OREXIGEN and OREXIGEN disagrees with CHEMI that the [* * *] changes are necessary [* * *], then OREXIGEN shall, within [* * *] ([* * *]) days of receipt of such notice from CHEMI, notify CHEMI
in writing of OREXIGEN’s disagreement and the rationale for such disagreement. The

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
Parties shall thereafter attempt in good faith to agree upon whether such change is necessary and who shall bear the costs due to such change by negotiation and consultation between appropriate
representatives of each of the Parties. In the event said representatives are unable to reach a consensus within [* * *] ([* * *]) days, such dispute shall be resolved in accordance with Section 13.3. CHEMI’s costs to
manufacture Bupropion Hydrochloride hereunder shall be determined from [* * *] on a consistent basis and in accordance with CHEMI’s standard accounting practices. Reasonably promptly after each [* * *], CHEMI shall give
OREXIGEN written notice of CHEMI’s costs to manufacture Bupropion Hydrochloride as of such date. 

  

	5.4.	CHEMI shall issue its invoice to OREXIGEN at the time of shipment. Each invoice shall set forth the applicable Price for the shipment properly determined in accordance
with the provisions of this Agreement. Payment of the invoice by OREXIGEN shall be within [* * *] ([* * *]) days following receipt of such invoice. Payment shall be subject to the inspection and acceptance procedures set forth in
Section 6. OREXIGEN may withhold a portion of any invoice that it disputes in good faith pending resolution of such dispute. All invoices and payments shall be in U.S. Dollars. 

  

	6.	INSPECTION OF SHIPMENTS 

  

	6.1.	OREXIGEN shall visually inspect or have visually inspected the Bupropion Hydrochloride delivered hereunder for obvious damage and/or shortage (collectively,
“Obvious Damage”) after receipt thereof and shall provide CHEMI with written notice of any such Obvious Damage within [* * *] ([* * *]) days after receipt. OREXIGEN shall be deemed to have accepted any shipment
of Bupropion Hydrochloride, but only with respect to Obvious Damage, unless CHEMI receives the written notice required within the [* * *] ([* * *])-day time period specified above. At its discretion, OREXIGEN may also test, or
have tested, any lot of Bupropion Hydrochloride supplied to OREXIGEN. 

  

	6.2.	At any time within [* * *] ([* * *]) months after receipt of any lot of Bupropion Hydrochloride but within [* * *] ([* * *])
days after discovery, OREXIGEN may provide CHEMI with written notice of any non-obvious damage, including adulteration of the Bupropion Hydrochloride, failure to meet Specifications, or other latent damage or defect (collectively,
“Non-Obvious Damage”). Obvious Damage and Non-Obvious Damage shall hereinafter be collectively referred to as “Damage.” 

  

	6.3.	OREXIGEN may reject any portion of any shipment of Bupropion Hydrochloride which contains any Damage by providing written notice to CHEMI of its rejection. OREXIGEN
agrees to provide CHEMI’s Quality Control Department with documentation of Damage to confirm the existence thereof in connection with any notice of rejection. 

  

	6.4.	 If CHEMI and OREXIGEN disagree as to the existence of Damage, then they will diligently and in good faith repeat the analyses of samples from the
shipment in question and implement suitable controls to determine the source of the discrepancy in results and the cause of any detected Damage, applying all objective and sound principles of

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
scientific investigation. If after such repeated analyses the disagreement is not resolved within [* * *] ([* * *]) days after the date of OREXIGEN’s notice, the Parties
will then submit representative samples of the shipment to a mutually acceptable independent testing lab and the results of said lab shall be binding on CHEMI and OREXIGEN. The costs associated with such submission shall be borne by the Party
against which the lab decided. 

  

	6.5.	Provided OREXIGEN provides notice of the damage claimed within [* * *] ([* * *]) days of receipt of the allegedly Damaged Bupropion Hydrochloride in
the case of Obvious Damage and within [* * *] ([* * *]) days after discovery, and in any case within [* * *] ([* * *]) months of receipt of the allegedly Damaged Bupropion Hydrochloride in the case of
Non-Obvious Damage, whether or not CHEMI accepts OREXIGEN’s basis for rejection, CHEMI shall promptly, on receipt of a notice of rejection and/or shortage, at OREXIGEN’s request and at no additional cost to OREXIGEN (including, without
limitation, the cost of transportation, export or import duties, if any, taxes, insurance and handling costs), deliver to OREXIGEN quantities of replacement Bupropion Hydrochloride equal to the rejected or short quantities as soon as reasonably
practicable thereafter, and in no event more than [* * *] ([* * *]) days after such notice is given and OREXIGEN shall have no obligation to pay for such Bupropion Hydrochloride until such time as conforming replacement Bupropion
Hydrochloride has been received. CHEMI will use expedited means of transport, if so requested by OREXIGEN at OREXIGEN’s expense unless such Bupropion Hydrochloride being replaced is determined to have been damaged. 

  

	6.6.	Notwithstanding any other provisions of this Agreement, OREXIGEN agrees, if so requested by CHEMI, to return to CHEMI, at CHEMI’s expense, any Bupropion
Hydrochloride that is, or is claimed to be, Damaged or otherwise to dispose of such Bupropion Hydrochloride as CHEMI may request. 

  

	7.	CONFIDENTIALITY 

  

	7.1.	During the term of this Agreement, the Parties may disclose certain confidential and proprietary information and data to each other relating to their respective
products, including active pharmaceutical ingredients and Finished Products (“Products”) and businesses, including, but not limited to financial and other business information, Product samples, formulas, manufacturing processes,
specifications, drawings, schematics and other technical, customer and Product development plans, forecasts, strategies and other data. Except as otherwise specifically provided herein, all information disclosed by one Party (in such capacity, the
“Disclosing Party”) to the other Party (in such capacity, the “Receiving Party”) relating to the Disclosing Party’s Products and/or its business operations and the results, reports, etc., of testing and
evaluation of any such information shall constitute “Proprietary Information.” 

  

	7.2.	Proprietary Information disclosed by a Disclosing Party to a Receiving Party hereunder shall be used by the Receiving Party solely in connection with exercising its
rights or performing its obligations under this Agreement. 

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	7.3.	In consideration of the Disclosing Party’s disclosure and supply of Proprietary Information, each Party, as a potential Receiving Party, agrees that, for the term
of the Agreement and for a period of [* * *] ([* * *]) years thereafter, it shall use the Disclosing Party’s Proprietary Information exclusively to conduct the activities contemplated under this Agreement. Each Party further
agrees, as a potential Receiving Party, for the term of the Agreement and for a period of [* * *] ([* * *]) years thereafter, it shall not disclose, without the express written consent of the Disclosing Party, any Proprietary
Information, including this Agreement or the interest of the Disclosing Party in exploring the possibility of entering into a business relationship with the Receiving Party, to any person other than to those employees, consultants or agents of the
Receiving Party (“Representatives”) who will be directly involved in fulfilling the Receiving Party’s obligations under this Agreement, provided that such Representatives have assumed like obligations of confidentiality in
writing to the Disclosing Party. Notwithstanding the foregoing, (a) OREXIGEN may disclose the existence and terms of this Agreement to bona fide potential investors, acquirers, corporate partners and financial advisors and (b) CHEMI may
disclose the existence (but not the terms of) this Agreement to bona fide potential investors and financial advisors. 

  

	7.4.	Each Party, as a potential Receiving Party, agrees to advise those of its Representatives who receive Proprietary Information (and such other persons who may receive
Proprietary Information as permitted by 7.3(a) or 7.3(b) above) that such information (a) is proprietary and confidential to the Disclosing Party and (b) shall not be disclosed to anyone except as authorized herein. Each Party further
agrees to take such reasonable precautions as it normally takes with its own confidential and proprietary information to prevent unauthorized disclosure or use of such Proprietary Information. 

  

	7.5.	In the event that the Receiving Party is required by any government regulation, law, court order or rule or otherwise becomes legally compelled to disclose any
Proprietary Information, it will provide the Disclosing Party with prompt advance notice in writing so that the Disclosing Party may, at its discretion, reasonably intervene prior to disclosure. The Receiving Party shall disclose only that portion
of Proprietary Information which its legal counsel determines it is required to disclose and will exercise its commercially reasonable efforts to obtain reliable assurance that confidential treatment will be accorded to such Proprietary Information.

  

	7.6.	 Notwithstanding any of the foregoing, the term “Proprietary Information” and the obligation of confidentiality associated therewith shall not
apply to the following information: (a) information which, at the time of the Disclosing Party’s disclosure to the Receiving Party, is publicly known; (b) information which, after the Disclosing Party’s disclosure to the
Receiving Party, becomes publicly known, except where such knowledge is the result of the Receiving Party’s breach of this Agreement or otherwise is the result of any unauthorized disclosure by any of its employees or Representatives;
(c) information which, prior to the Disclosing Party’s disclosure to the Receiving Party, was already in the Receiving Party’s possession, as evidenced by its prior written records; or (d) information which, subsequent to the
Disclosing Party’s disclosure to the Receiving Party, is obtained by the Receiving Party from a third Party which is lawfully in possession of such information and not subject to a contractual or fiduciary relationship

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
to the Disclosing Party with respect thereto; or (e) information which was independently developed by or for Receiving Party by an individual without access to, reference of, incorporation
of or use of the Proprietary Information, but in any event, without violating the terms of this Agreement. 

  

	7.7.	Upon the termination of this Agreement, the Receiving Party shall, if so requested by the Disclosing Party, promptly return to the Disclosing Party the originals and
all copies of any Proprietary Information then in the Receiving Party’s possession. Notwithstanding the foregoing, Receiving Party may retain one copy of such Proprietary Information for archival purposes. 

  

	8.	QUALITY OF BUPROPION HYDROCHLORIDE; REGULATORY MATTERS;
REPRESENTATIONS AND WARRANTIES 

  

	8.1.	CHEMI hereby represents, warrants and covenants as follows: 

  

	 	8.1.1.	At all times during the term of this Agreement, CHEMI’s facilities shall remain in compliance with, and the Bupropion Hydrochloride shall be manufactured and
delivered in compliance with, all applicable laws, regulations and standards, including but not limited to, the provisions of the Federal Food, Drug, and Cosmetic Act, as amended from time to time (the “Act”); the FDA’s cGMP,
including the FDA’s Guidance for Industry, Manufacturing, Processing or Holding Active Pharmaceutical Ingredients, March 1998, and any updates thereto; the FDA’s regulations for drug establishment registration; the Specifications; the
other rules and regulations promulgated under the Act relating to the manufacture of pharmaceutical products; and equivalent laws, regulations and standards promulgated by Regulatory Agencies in all jurisdictions for which OREXIGEN has given notice
to CHEMI (collectively, the “Applicable Laws”). 

  

	 	8.1.2.	No Bupropion Hydrochloride constituting or being a part of any shipment to OREXIGEN shall at the time of any such shipment be adulterated within the meaning of the Act,
or the rules and regulations promulgated there under, as such law, rule or regulation is constituted and in effect at the time of any such shipment. 

  

	 	8.1.3.	All Bupropion Hydrochloride supplied to OREXIGEN hereunder (i) shall comply with the Specifications; (ii) shall have been manufactured, stored and shipped in
accordance with the Specifications, applicable approvals from Regulatory Agencies and all Applicable Laws, (iii) may be introduced into public commerce consistent with the intended use for Bupropion Hydrochloride pursuant to Applicable Laws,
and (iv) will have expiration dating of not less than thirty (30) months from the date of delivery in accordance with this Agreement. 

  

	 	8.1.4.	All necessary licenses, permits or approvals required by Applicable Laws in connection with the manufacture, storage, and shipment of Bupropion Hydrochloride hereunder,
including without limitation permits related to manufacturing facilities shall be obtained and maintained. 

	 	8.1.5.	CHEMI will (i) respond fully and accurately to all inquiries directed to it by the FDA or any other Regulatory Agency that may impact the quality or timely
delivery of Bupropion Hydrochloride and shall promptly notify OREXIGEN of same, (ii) assist OREXIGEN in responding to inquiries directed to OREXIGEN by the FDA or other Regulatory Agencies, and (iii) provide the FDA or other Regulatory
Agencies with such information and data as is requested by the FDA or other Regulatory Agencies with respect to the manufacture, use, route of synthesis and testing of the Bupropion Hydrochloride. 

  

	 	8.1.6.	CHEMI’s manufacturing facilities are, and shall at all times during the term of this Agreement be, in compliance with the FDA’s cGMP.

  

	 	8.1.7.	CHEMI has disclosed to OREXIGEN all warning letters or similar notices relating to its manufacturing facilities or import alerts (including FDA Form 483’s), if
any, for products manufactured in its facilities issued during the last five (5) years and CHEMI will during the term disclose in timely fashion all such letters, alerts and notices. 

  

	 	8.1.8.	CHEMI has, and shall maintain, sufficient facilities, personnel and resources to meet its obligations to supply Bupropion Hydrochloride under this Agreement.

  

	 	8.1.9.	CHEMI is not aware of any claim by a third party that the Bupropion Hydrochloride supplied hereunder or its process for manufacturing the Bupropion Hydrochloride
supplied hereunder would, if carried out in the United States, or in any other country where generic Bupropion Hydrochloride is manufactured or sold, infringe, misappropriate or violate any patent, trade secret or other intellectual property right
in effect in such countries. 

  

	 	8.1.10.	To CHEMI’s knowledge ([* * *]), the Bupropion Hydrochloride supplied to OREXIGEN under this Agreement and CHEMI’s process for manufacturing the Bupropion
Hydrochloride supplied hereunder will not infringe, misappropriate or violate any patent, trade secret or other intellectual property right in effect during the term of this Agreement in the United States. 

  

	 	8.1.11.	There are no pending or threatened claims against CHEMI asserting that any of the activities of CHEMI relating to the manufacture, import, use and sale of Bupropion
Hydrochloride in the United States or the conduct of the activities contemplated herein by OREXIGEN, infringe, misappropriate or violate the rights of any third party. 

  

	8.2.	OREXIGEN hereby represents, warrants and covenants that, to OREXIGEN’s knowledge ([* * *]), the Finished Product will not infringe, misappropriate or violate any
third party patent, trade secret or other intellectual property right in effect during the term of this Agreement in the United States (provided, that OREXIGEN’s representation does not extend to any infringement, misappropriation or violation
that arises out of or relates to the Bupropion Hydrochloride or the process for manufacturing the Bupropion Hydrochloride). 

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	8.3.	Each Party represents and warrants that all corporate action on its part and on the part of each of its officers and directors necessary for the authorization,
execution and delivery of this Agreement has been taken, it has the full right and authority to enter into this Agreement and perform its obligations hereunder and that it is not aware of any obligations owed to third parties that would conflict
with its ability to perform its obligations hereunder. 

  

	8.4.	If requested in writing by OREXIGEN, CHEMI shall permit OREXIGEN or its authorized representatives to inspect CHEMI’s facilities and records and be given access to
CHEMI’s personnel (at reasonable times, upon reasonable advance notice and in the company of a CHEMI representative during normal business hours), to the extent OREXIGEN deems reasonably necessary to enable OREXIGEN to verify compliance by
CHEMI with its obligations under this Agreement and to verify compliance with any Applicable Laws. 

  

	8.5.	CHEMI shall provide to OREXIGEN yearly confirmation that it has timely filed with the FDA and all other relevant Regulatory Agencies, any required DMF-related filings.

  

	8.6.	OREXIGEN shall provide CHEMI copies of product complaints, or notices or inquiries from the FDA or other Regulatory Agencies, which raise issues with respect to the
manufacture or product quality of the Bupropion Hydrochloride provided by CHEMI to OREXIGEN. CHEMI shall fully and appropriately investigate such matters and provide OREXIGEN with a report of its investigation. In the event that CHEMI receives any
complaint, claims or adverse reaction reports regarding Bupropion Hydrochloride, including notices from the FDA regarding any alleged regulatory noncompliance of Bupropion Hydrochloride, CHEMI shall promptly and not more than [* * *] ([* * *])
business days after receipt, provide to OREXIGEN all information contained in the complaint, report or notice and such additional information regarding Bupropion Hydrochloride as OREXIGEN may reasonably request. CHEMI shall comply, at a minimum,
with FDA requirements for complaint handling with respect to such complaints, claims or adverse reaction reports. 

  

	8.7.	OREXIGEN and CHEMI each further represents and warrants, for itself, that it shall comply with all Applicable Laws in the performance of its obligations hereunder.

  

	8.8.	 CHEMI shall promptly notify OREXIGEN of any problems or unusual production situations which have, or are reasonably likely to have, an adverse effect
on CHEMI’s ability to perform its obligations hereunder or to deliver the Bupropion Hydrochloride to OREXIGEN in a timely manner. CHEMI will make its facilities available for inspection by representatives of any Regulatory Agency in compliance
with all Applicable Laws. In addition, CHEMI shall notify and, if applicable, provide copies of any notices or communications to, OREXIGEN of any FDA or other Regulatory Agency inspection, investigation or other inquiry or communication relating to
the manufacture of the Bupropion Hydrochloride or to any facility at which the Bupropion Hydrochloride is manufactured, including, but not limited to, any FDA FORM 483 or warning letter, promptly and not more than [* * *] ([* * *]) business days
after shall also discuss with OREXIGEN any response to observations and notifications received in connection with

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
any inspection, investigation, communication or other inquiry concerning Bupropion Hydrochloride and will give OREXIGEN an opportunity to comment upon any proposed response before it is made. Any
notices under this Section 8.8 shall not operate to relieve CHEMI of its obligations to deliver the ordered amounts of Bupropion Hydrochloride or affect OREXIGEN’s right to pursue any remedies that might be available to it.

  

	8.9.	Both Parties covenant that it will not in the performance of its obligations under this Agreement use the services of any person debarred or suspended under 21 U.S.C.
§35(a) or (b). Both Parties represent that it does not currently have, and covenants that it will not hire, as an officer or an employee, any person who has been convicted of a felony under the laws of the United States for conduct relating to
the regulation of any drug product under the Act. 

  

	8.10.	Both Parties shall maintain commercial general liability insurance and product liability insurance with a minimum limit per occurrence or accident of $[* * *] and an
annual aggregate limit of $[* * *] for the term of this Agreement and for [* * *] ([* * *]) years thereafter. Upon request, either Party will provide to the other Party copies of insurance certificates reflecting the above.

  

	8.11.	CHEMI shall immediately notify OREXIGEN of any information of the following kind about Bupropion Hydrochloride provided to OREXIGEN: 

  

	 	8.11.1.	information indicating that shipped product has not been manufactured or supplied in accordance with the Specifications, cGMP, this Agreement or in compliance with
Applicable Laws; and 

  

	 	8.11.2.	information concerning any bacteriological contamination, or any significant chemical, physical or other changes or deterioration in the shipped Bupropion
Hydrochloride, or the failure of one or more shipped lots of Bupropion Hydrochloride to meet Specifications, including stability parameters. 

  

	8.12.	Without limiting the foregoing, the Parties shall enter into a Quality Agreement within six (6) months of the date of the execution of this Agreement (the
“Quality Agreement”). In the event there is any conflict in the terms and provisions of this Agreement and the Quality Agreement, the terms and provisions of this Agreement shall control and prevail. 

  

	8.13.	EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NO PARTY MAKES ANY WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	9.	INDEMNIFICATION 

  

	9.1.	OREXIGEN hereby agrees to and shall defend, indemnify, and hold harmless CHEMI, its affiliates and each of their respective employees, officers, directors and agents
(the “Supplier Indemnitees”), from, against, and in respect of, any and all losses, judgments, damages, liabilities, suits, actions, expenses (including reasonable attorney’s fees), and proceedings arising from any claims of
any third party to the extent resulting from: 

  

	 	9.1.1.	any misrepresentation, breach of warranty, or the non-fulfillment of any obligation, covenant, or duty on the part of OREXIGEN under this Agreement;

  

	 	9.1.2.	any claim, complaint, suit, proceeding or cause of action against any of the Supplier Indemnitees alleging physical injury or death, brought by or on behalf of an
injured party, or loss of service or consortium or a similar such claim, complaint, suit, proceeding or cause of action brought by a spouse, relative or companion of an injured party due to such physical injury or death, and in each case arising out
of the Finished Products; 

  

	 	9.1.3.	any negligence or willful misconduct of OREXIGEN, its employees, officers and directors in performing this Agreement; and 

  

	 	9.1.4.	any claim of patent infringement relating to a Finished Product or the process for manufacturing a Finished Product (excluding any claim of patent infringement arising
out of or relating to the Bupropion Hydrochloride or the process for manufacturing the Bupropion Hydrochloride), which claim, if true, would be in contravention of the representations, warranties and covenants of OREXIGEN hereunder;

 Except to the extent resulting from (i) any misrepresentation, breach of warranty, or the non-fulfillment
of any obligation, covenant, or duty on the part of CHEMI under this Agreement, (ii) any negligence or willful misconduct of the Supplier Indemnitees in performing this Agreement, or (iii) any claim subject to CHEMI’s indemnification
obligations under Section 9.2. 
  

	9.2.	CHEMI hereby agrees to and shall defend, indemnify, and hold harmless OREXIGEN, its affiliates and each of their respective employees, officers, directors and agents
(the “OREXIGEN Indemnitees”), from, against, and in respect of, any and all losses, judgments, damages, liabilities, suits, actions, expenses (including reasonable attorney’s fees), and proceedings arising from any claims of
any third party to the extent resulting from: 

  

	 	9.2.1.	any misrepresentation, breach of warranty, or the nonfulfillment of any obligation, covenant, or duty on the part of CHEMI under this Agreement;

  

	 	9.2.2.	any claim, complaint, suit proceeding or cause of action against any of the OREXIGEN Indemnitees alleging physical injury or death, brought by or on behalf of an
injured party, or loss of service or consortium or a similar such claim, complaint, suit, proceeding or cause of action brought by a spouse, relative or 

 companion of an injured party due to such physical injury or death, and in each case arising
out of the Bupropion Hydrochloride supplied by CHEMI to OREXIGEN; 
  

	 	9.2.3.	any negligence or willful misconduct of CHEMI or its employees, officers or directors in performing this Agreement; and 

  

	 	9.2.4.	any claim of patent infringement relating to the Bupropion Hydrochloride supplied to OREXIGEN or the process for manufacturing the Bupropion Hydrochloride supplied to
OREXIGEN which claim, if true, would be in contravention of the representations, warranties and covenants of CHEMI hereunder; 

 Except to the extent resulting from (i) any misrepresentation, breach of warranty, or the non-fulfillment of any obligation, covenant, or duty on the part of OREXIGEN under this Agreement,
(ii) any negligence or willful misconduct of the OREXIGEN Indemnitees in performing this Agreement, or (iii) any claim subject to OREXIGEN’s indemnification obligations under Section 9.1. 
  

	9.3.	 The foregoing indemnification obligations are subject to the following: (a) the indemnifying Party must be notified by or on behalf of the
indemnified Party in writing promptly after a claim is made, a suit is filed or an action or investigation is initiated (each, a “Proceeding”) against the indemnified Party, unless such delay does not materially prejudice the
indemnifying Party; (b) subject to the provisions set forth below in this Section 9.3, the indemnifying Party shall be permitted to defend, control, conduct and prosecute, in the indemnifying Party’s sole discretion and by counsel of
the indemnifying Party’s choosing, the defense of such Proceeding brought against the indemnified Party; (c) the indemnifying Party shall have the right in its sole discretion to settle, compromise or otherwise terminate the Proceeding
solely upon the payment of money; provided, that, there is no finding or admission of any violation by any indemnified Party of (i) any law, rule or regulation or (ii) the rights of any person; and provided, further, that, no such
settlement shall prohibit any indemnified Party from importing the Bupropion Hydrochloride into the United States and or making, using or selling products in the United States and made from such Bupropion Hydrochloride; (d) the indemnified
Party shall refrain from settling (or endeavoring to settle, or entering into settlement negotiations with respect to) any such Proceeding without the indemnifying Party’s prior written consent; (e) except as may otherwise be required by
law, the indemnified Party shall not compromise the position of the indemnifying Party by admission, statements, disclosure or conduct (collectively, “Disclosure”) in a way that could prejudice the defense, control, conduct or
prosecution of said cause of action (it being understood that no indemnified Party shall be deemed to have violated this provision so long as such Party has acted in good faith to fulfill its obligations under this provision); and (f) the
indemnified Party shall cooperate with the indemnifying Party in the defense, conduct, prosecution or termination of the Proceeding, including the furnishing of information and the assistance from employees of the indemnified Party at the
indemnifying Party’s reasonable request and expense. With respect to clause (e) above, the indemnified Party will provide the indemnifying Party with prompt written notice in advance of any such Disclosure being made to permit the
indemnifying Party to

	 	 
seek an appropriate protective order, restriction on response or withdrawal of the request for Disclosure. If, however, any such request for relief by the indemnifying Party is denied or is
otherwise unavailable, the relevant indemnified Party may make the Disclosure without any liability to the indemnifying Party. The indemnified Party may, at its option and expense, participate in the indemnifying Party’s defense with counsel of
its own choosing, and if the indemnified Party so participates, the Parties shall cooperate with one another in such defense in a commercially reasonable fashion. Notwithstanding any provision in this Agreement to the contrary, OREXIGEN shall at all
times have the right to assume direction and control of the defense of any claim alleging infringement, misappropriation or violation of any patent, trade secret or other intellectual property right of any third party, provided that OREXIGEN will
provide CHEMI with a reasonable opportunity to review and consult from time to time concerning the strategy and action plan (including possibly pursuing one or more licenses as appropriate), and in such event CHEMI shall cooperate and assist as
requested in the defense of such claim and if OREXIGEN finds it necessary or desirable to join CHEMI as a party, CHEMI shall execute all papers or perform such other acts as may reasonably be required by OREXIGEN. Further, CHEMI shall not settle or
consent to the entry of any judgment with respect to any such claim, without OREXIGEN’s prior written consent. In the event OREXIGEN assumes the direction and control of the defense of any claim alleging infringement, misappropriation or
violation of any patent, trade secret or other intellectual property rights of any third party, [* * *] in connection with the defense of such claim. 

  

	9.4.	The indemnification rights provided for herein are in addition to, and not in substitution for, any and all remedies available to a Party under this Agreement or
otherwise at law or in equity. Notwithstanding anything to the contrary in this Section 9, each Party may, and expressly reserves the right to, seek judicial relief from any court of competent jurisdiction in order to obtain an injunction or
other equitable relief. 

  

	9.5.	IN NO EVENT SHALL ANY OF THE PARTIES HERETO BE RESPONSIBLE OR LIABLE TO THE OTHER UNDER ANY PROVISION OF THIS AGREEMENT OR UNDER ANY THEORY OF NEGLIGENCE, STRICT
LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, OR EXEMPLARY DAMAGES OR LOST PROFITS. FOR THE PURPOSE OF CLARITY, NOTHING IN THIS SECTION IS INTENDED TO LIMIT THE INDEMNIFICATION OBLIGATIONS OF ANY PARTY WITH
RESPECT TO THE CHARACTERIZATION OF ANY CLAIM BY A THIRD PARTY AS CONSEQUENTIAL, INDIRECT, SPECIAL, OR EXEMPLARY DAMAGES OR LOST PROFITS. 

  

	10.	ADVERSE EVENT REPORTING; COSTS AND EXPENSES OF
RECALL 

  

	10.1.	 OREXIGEN shall have sole control and responsibility for reporting all adverse events associated with the use of Finished Products in humans, whether
expected or unexpected and whether or not considered drug related, including the following: (i) an adverse event occurring in the course of the use of a drug product in professional practice; (ii) an adverse event occurring from drug
overdose whether accidental or intentional; (iii) an

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
adverse event occurring from drug abuse; or (iv) an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action (collectively, “Adverse
Events”), with respect to the Finished Products, and responding to all Finished Product quality complaints and medical and technical inquiries, whether from lay persons, health care professionals and or Regulatory Agencies. Notwithstanding
the foregoing, to the extent CHEMI has an obligation to report any Adverse Events to any Regulatory Agencies it may do so provided it first provides written notice to OREXIGEN thereof and a copy of such report. CHEMI agrees to consider in good faith
any comments OREXIGEN has timely provided concerning such reports prior to CHEMI’s submission of the same to the applicable Regulatory Agency. In the event CHEMI (a) receives any information regarding any Adverse Event relating to
Bupropion Hydrochloride or any Finished Products or their manufacture, (b) receives any complaints relating, or potentially relating, to Bupropion Hydrochloride or any Finished Products or their manufacture, (c) receives any medical or
technical inquiry relating, or potentially relating, to Bupropion Hydrochloride or any Finished Products or their manufacture, or (d) discovers or is notified of any material defect in Bupropion Hydrochloride or any Finished Products, it shall
(i) notify OREXIGEN within [* * *] ([* * *]) days thereof, and (ii) promptly conduct an investigation in accordance with its approved written procedures for the surveillance, receipt, evaluation, and reporting of complaints, inquiries or
discoveries of that nature and report the results of such investigation to OREXIGEN promptly upon the completion thereof. 

  

	10.2.	OREXIGEN shall have sole control and responsibility for conducting all voluntary and involuntary recalls or other related action (collectively,
“Recalls”) of units of any Finished Product; provided, however, that CHEMI agrees to reimburse OREXIGEN for all of its reasonable costs and expenses incurred with respect to any Recalls arising out of any of the causes set forth in
Sections 9.2.1 through 9.2.4. Further, in the event of any Recall of any Finished Products arising out of any of the causes set forth in Sections 9.2.1 through 9.2.4, OREXIGEN’s obligation to pay CHEMI for Bupropion Hydrochloride purchased
hereunder shall cease. This Section 10 is intended to augment and not limit the indemnification provisions of Section 9 herein. 

  

	11.	TERM AND TERMINATION 

  

	11.1.	This Agreement shall commence on the Effective Date and shall continue in effect until the date that is four (4) years from the Qualification Date (the
“Initial Term”), unless earlier terminated or extended in accordance with it terms. This Agreement shall be automatically renewed for additional two (2) year terms unless written notice of intent to terminate is provided by
OREXIGEN at least three (3) months prior to the expiration of the Initial Term or any extension term, as applicable. 

  

	11.2.	 This Agreement may be terminated by (i) OREXIGEN upon [* * *] ([* * *]) days written notice to CHEMI of a failure by CHEMI to perform or observe
any material covenant, condition or agreement to be performed or observed by it under this Agreement, unless such breach has been cured within the [* * *] ([* * *])-day notice period, and (ii) CHEMI upon [* * *] ([* * *]) days written
notice to OREXIGEN of a failure by OREXIGEN to perform or observe any material covenant, condition or agreement to be performed or observed by it under this Agreement, unless such breach has been cured within the [* * *] ([* * *])-day notice period;
provided, however, that with respect to a failure to timely

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	 	 
supply ordered quantities of Bupropion Hydrochloride under this Agreement, CHEMI shall have the right to cure such breach no more than once during the term of this Agreement unless otherwise
agreed by OREXIGEN in writing; and provided further, that if the breach by OREXIGEN is a failure to pay an invoice when due (except as provided in Section 5.8), then the notice and cure period shall be [* * *] ([* * *]) days.

  

	11.3.	OREXIGEN may terminate this Agreement effective immediately upon written notice to CHEMI in the event that (a) CHEMI dissolves, is declared insolvent or bankrupt
by a court of competent jurisdiction; (b) a voluntary or involuntary petition of bankruptcy is filed in any court of competent jurisdiction by CHEMI; or (c) this Agreement is assigned by CHEMI for the benefit of creditors. CHEMI may
terminate this Agreement effective immediately upon written notice to OREXIGEN in the event that (a) OREXIGEN dissolves, is declared insolvent or bankrupt by a court of competent jurisdiction; (b) a voluntary or involuntary petition of
bankruptcy is filed in any court of competent jurisdiction by OREXIGEN; or (c) this Agreement is assigned by OREXIGEN for the benefit of creditors. 

  

	11.4.	Either Party may terminate this Agreement effective immediately upon written notice to the other Party in the event that (a) any Regulatory Agency takes any
action, or raises any objection, that prevents OREXIGEN from importing, exporting, purchasing or selling either the Bupropion Hydrochloride or the Finished Product (b) the Finished Product fails during clinical trials and OREXIGEN withdraws its
NDA; (c) OREXIGEN determines, in its sole discretion, to no longer pursue the development and/or commercialization of a Finished Product which contains Bupropion Hydrochloride; or (d) a legal proceeding shall be instituted against CHEMI,
which is reasonably likely to materially adversely affect CHEMI’s ability to properly perform under this Agreement or subject OREXIGEN to any material risk of liability or loss. 

  

	11.5.	In the event of termination of this Agreement by OREXIGEN pursuant to Section 11.4, OREXIGEN agrees to pay for previously placed orders of Bupropion Hydrochloride
but not yet delivered to OREXIGEN, provided that CHEMI shall use reasonable commercial efforts to mitigate the amount of such payments by OREXIGEN, including, but not limited to, selling such Bupropion Hydrochloride to other customers, and provided
further that CHEMI shall deliver Bupropion Hydrochloride pursuant to such orders in accordance with this Agreement. 

  

	11.6.	The provisions of this Section 11 as to termination shall not limit or restrict the rights of any Party to seek remedies or take measures that may be otherwise
available to it at law or equity in connection with the enforcement and performance of obligations under this Agreement. 

  

	12.	NOTICES 

 Any and all notices required to be given under this Agreement will be in writing and effective upon receipt, sent by facsimile transmission, mailed postage prepaid by first-class certified or registered mail, or sent by express courier
service, at the respective addresses, as follows: 
  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 IF TO OREXIGEN, TO: 
 Orexigen Therapeutics, Inc. 
 3344 N. Torrey Pines Court 
 Suite 200 
 La
Jolla, CA 92037 
 Attention: Walt Piskorski 
 Telephone Number: (858) 875-8600 
 Facsimile Number: (858) 875-8650

 With a copy to: 
 Orexigen Therapeutics, Inc. 
 3344 N. Torrey Pines Court 
 Suite 200 
 La
Jolla, CA 92037 
 Attention: General Counsel 
 Telephone Number: (858) 875-8600 
 Facsimile Number: (858) 875-8650

 With an additional copy to (which shall not by itself constitute notice): 
 Latham & Watkins LLP 
 12636 High Bluff Drive, Suite 400 
 San Diego, CA 92130 
 Attention: Cheston J. Larson, Esq. 
 Telephone Number: (858) 523-5400 
 Facsimile Number: (858) 523-5450

 IF TO CHEMI, TO: 
 CHEMI S.p.A. 
 Via dei Lavoratori, 54 
 20092 Cinisello Balsamo (Milan) Italy 
 Attention: Mr. Paolo Oligeri

 Telephone Number: +39 02 64431 
 Facsimile Number: +39 02 6128960 
  

	13.	MISCELLANEOUS 

  

	13.1.	 Force Majeure. In the event that any Party hereto is prevented from complying, either in whole or in part, with any of the terms or provisions
of this Agreement by reason of fire, flood, storm, strike or lockout, riot, war, rebellion, lack or failure of transportation facilities, court order, accident, or Acts of God, and to the extent that the foregoing are

	 	 
beyond a Party’s reasonable control, then, unless conclusive evidence to the contrary is provided, upon written notice by the Party whose performance is so affected to the other,

 the requirements of this Agreement so affected (to the extent affected) shall be suspended during the period of, and only
to the extent of, such disability. Said Party shall be excused by reason of said force majeure only so long as it is exercising its best efforts to overcome said reason. Notwithstanding the foregoing, if a force majeure event prevents a Party’s
performance under this Agreement for an aggregate of more than [* * *] days, the other Party may terminate this Agreement upon written notice to the non-performing Party. 
  

	13.2.	Assurances. Each Party to this Agreement shall execute, acknowledge and deliver such further instruments and documents, and do all such other acts and things as
may be required by law or as may be necessary or advisable to carry out the intents and purposes of this Agreement. The Parties will cooperate with each other and offer reasonable assistance in carrying out their respective responsibilities under
this Agreement. 

  

	13.3.	Governing Law and Exclusive Jurisdiction. This Agreement shall be governed by and construed under the laws of the State of California (USA), excluding its
conflicts of law provisions. Exclusive jurisdiction and venue for any legal actions or proceedings relating to or arising from this Agreement shall be vested with the federal and state courts located in the City and County of San Francisco in the
State of California (USA). 

  

	13.4.	Severability. If any provision of this Agreement shall be held to be invalid, illegal, or unenforceable, the validity, legality, or enforceability of the
remaining provisions hereof shall not in any way be affected or impaired thereby unless the purposes of the Agreement cannot be achieved. In the event any provision shall be held invalid, illegal, or unenforceable the Parties shall use best efforts
to substitute a valid, legal, and enforceable provision which insofar as practical implements the purposes hereof. 

  

	13.5.	No Assignment. No Party shall assign its rights and/or obligations under this Agreement without the prior written consent of the other Party hereto, except that
either Party may assign this Agreement in connection with the transfer, license or sale of all or substantially all of its assets or business to which the subject matter of this Agreement relates or in connection with any merger, consolidation or
reorganization, without the other Party’s prior written consent. 

  

	13.6.	Waiver. No delay, waiver, omission or forbearance on the part of any Party to exercise any right, option, duty or power arising out of any breach or default by
any other Party of any of the terms, provisions or covenants hereof, will constitute a waiver by such Party of its rights to enforce any such right, option, duties or power as against the other Party hereto, or its rights as to any subsequent breach
or default by the other Party. 

  

	13.7.	Survival. Upon termination or expiration of this Agreement, the obligations of the Parties which by their nature should survive and the obligations under
Sections 7-13 of this Agreement and under any existing confidentiality agreements between the Parties shall survive. 

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

	13.8.	Entire Agreement. This Agreement and the Schedules and Appendices attached hereto, the confidentiality agreements referenced in Section 13.8 and the Quality
Agreement constitute the full understanding and entire agreement between the Parties and supersede any and all prior oral or written understandings and agreements with respect to the subject matter hereof. No terms, conditions, understandings, or
agreements purporting to modify, amend, waive or terminate this Agreement, or any provision hereof, shall be binding except by the execution of a writing specified to be an explicit amendment to this Agreement duly executed by the authorized
signatories of the Parties hereto. No modification, waiver, termination, rescission, discharge or cancellation of any right or claim under this Agreement shall affect the right of any Party to enforce any other claim or right hereunder.

  

	13.9.	Binding Agreement. Subject to Section 13.6, this Agreement shall be binding upon the Parties and their respective successors and permitted assigns and shall
insure to the benefit of the Parties and their respective successors and permitted assigns. 

  

	13.10.	Headings. The headings used in this Agreement are for convenience of reference only and are not a part of the text hereof. 

  

	13.11.	Counterparts. This Agreement may be executed in counterparts, each of which shall constitute an original and all of which shall together constitute a single
agreement. 

 [Remainder of This Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, the Parties hereby agree to the terms and conditions of this Agreement. 
  

									
	OREXIGEN THERAPEUTICS, INC.	 		 	CHEMI S.P.A.
					
	By:	 	  
	 		 	By:	 	  

	Name:	 	Walter Piskorski	 		 	Name:	 	  

	Title:	 	Vice President, Technical Operations	 		 	Title:	 	  

	Date:	 	December 15, 2009	 		 	Date:	 	  

 [SIGNATURE PAGE TO BUPROPION HYDROCHLORIDE SUPPLY AGREEMENT] 

 LIST OF DEFINED TERMS 
  

			
	 DEFINED TERM
	  	 SECTION

	 Act
	  	8.1.1
	 Adverse Events
	  	10.1
	 Agreement
	  	Preamble
	 ANDA
	  	2.3
	 Applicable Laws
	  	8.1.1
	 cGMP
	  	2.4
	 CHEMI
	  	Preamble
	 Commercial Launch
	  	3.2
	 Damage
	  	6.2
	 Disclosing Party
	  	7.1
	 Disclosure
	  	9.3
	 DMF
	  	2.1
	 Effective Date
	  	Preamble
	 FDA
	  	2.1
	 Finished Products
	  	2.1
	 Firm Commitment
	  	3.1
	 Firm Commitment Purchase Order
	  	3.3
	 Initial Term
	  	11.1
	 NDA
	  	2.3
	 Non-Obvious Damage
	  	6.2
	 Obvious Damage
	  	6.1
	 OREXIGEN
	  	Preamble
	 OREXIGEN Indemnitees
	  	9.2
	 Party
	  	Preamble
	 Parties
	  	Preamble
	 Price
	  	5.2
	 Proceeding
	  	9.3
	 Products
	  	7.1
	 Proprietary Information
	  	7.1
	 Purchase Order
	  	1.2
	 Qualification Date
	  	3.2
	 Quality Agreement
	  	8.12
	 Recalls
	  	10.2
	 Receiving Party
	  	7.1
	 Regulatory Agency
	  	2.2
	 [* * *] Price Change
	  	5.4
	 Representatives
	  	7.3
	 Rolling Forecast
	  	3.1
	 Specifications
	  	2.1
	 [* * *] Price Change
	  	5.4
	 Supplier Indemnitees
	  	9.1

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 SCHEDULE A 
 SPECIFICATIONS 
 [* * *] 
  

									
	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]	 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

									
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

									
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 		 		 		 	
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

									
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 		 		 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 	[* * *]	 		 	[* * *]
					
	[* * *]	 	[* * *]	 		 	[* * *]	 	[* * *]

 [* * *] 
  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 SCHEDULE B 
 PRICING AND SHIPPING TERMS 
 Freight Terms: CHEMI shall make all
necessary shipping arrangements to OREXIGEN’s designated facility, CIP (Incoterms 2000) OREXIGEN’s designated facility, freight prepaid. 
 Shipping Method: Air Freight 
 Price: 
 The initial Price, which shall be subject to adjustment in accordance with Section 5.3, shall be as follows: 
  

					
	 [* * *]
	  	 [* * *]
	  	  
	[* * *]	  	[* * *]	  
	[* * *]	  	[* * *]	  
	[* * *]	  	[* * *]	  
	[* * *]	  	[* * *]	  
	[* * *]	  	[* * *]	  
	[* * *]	  	[* * *]	  
	[* * *]	  	[* * *]	  
	
	[* * *]

  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 APPENDIX A 
 FORM OF PURCHASE ORDER 
 Orexigen Therapeutics, Inc.

 3344 North Torrey Pines Ct., Sutie 160 
 San Diego, CA 92130 
  

													
		  		  		  		  	 PURCHASE
 ORDER
	  	
		  		  		  		  	  
 Date
	  	  
 P.O. No.
	  	
		  		  		  		  	    	  	 	  	

  

													
	 Vendor
	  		  	Ship To
	 	  	 	  		  	As directed by Orexigen
	 	 		 			 
	 	  	 	  		  		  		  		  	 
	 	 		 			 
	 	  	 	  		  		  		  		  	 
	 	 		 			 
	 	  	 	  		  		  		  		  	 
	 	 		 			 
	 	  	 	  		  		  		  		  	 
	 	 		 			 
	 	  	 	  		  		  		  		  	 
	 	 		 			 
	 	  	 	  		  	 	  	 	  	 	  	 

  

													
	  
 Item
  
	  	  
 Description
  
	  	 	  	 	  	  
 Qty
  
	  	  
 Rate
  
	  	  
 Amount
  

	 				 	 	 
	 	  		  		  		  		  		  	 
	 				 	 	 
	 	  		  		  		  		  		  	 
	 				 	 	 
	 	  		  		  		  		  		  	 
	 				 	 	 
	 	  		  		  		  		  		  	 
	 				 	 	 
	 	  		  		  		  		  		  	 
	 				 	 	 
	 	  		  		  		  		  		  	 
	 				 	 	 
	 	  		  		  		  		  		  	 
	 				 	 	 
	 	  	 	  	 	  	 	  	 	  	 	  	 
		  		  		  		  	TOTALFourth Lease Amendment

 Exhibit 10.2e 
  

							
	NORTH CAROLINA	  	)	  		  	
		  	)	  		  	FOURTH LEASE AMENDMENT
	FORSYTH COUNTY	  	)	  		  	

 This Fourth Lease Amendment (the “Fourth Amendment”) is made
effective as of the 1st day of August, 2007 (the
“Amendment Date”), by and between Wake Forest University Health Sciences, a North Carolina non-profit corporation having its principal office in Winston-Salem, North Carolina (“Landlord”), and Targacept, Inc., a
Delaware corporation having its principal office in Winston-Salem, North Carolina (“Tenant”). Unless otherwise defined herein, all of the capitalized terms of this Fourth Amendment shall have the same meanings ascribed to them in
the Lease effective August 1, 2002, as amended by the First Lease Amendment effective January 1, 2005 (the “First Lease Amendment”), the Second Lease Amendment effective March 31, 2006 (the “Second Lease
Amendment”), and the Third Lease Amendment effective January 1, 2007 (the “Third Lease Amendment”) all of which are hereinafter collectively referred to as the “Lease.” 
 WITNESSETH: 
 WHEREAS, Tenant desires to Lease from Landlord and Landlord desires to lease to Tenant an additional 704 square feet located on the Basement Level of the Building, and designated as “B17 Server Room” on the Basement Level Floor
Plan attached as Exhibit A-2 upon the terms and for the rents as further set forth herein; and 
 NOW, THEREFORE, for and in
consideration of the premises, of the rents reserved and to be paid by Tenant to Landlord, and of the additional mutual covenants of the parties, the parties hereby agree to amend the Lease as follows: 
 1. The Lease is amended by: 
  

	 	a.	Deleting Exhibit A of the Lease, as amended, and substituting in lieu thereof the attached Exhibit A, describing the Demised Premises, and deleting
Exhibit A-2 and substituting in lieu thereof the attached Exhibit A-2, which reflects modifications to the “One Technology Place, Basement Level Floor Plan” only; and 

  

	 	b.	Deleting the table appearing in paragraph 3.1 of the Lease and substituting in lieu thereof the following table and accompanying notes: 

 “3.1 Tenant will pay annual rental pursuant to the following schedule (“rsf” indicates “rentable square foot”):

 Initial Term 
  

									
	 Effective Date
	  	Demised Premises
	  	3rd & 4th Floors
(40,432 rsf)	  	1,000 rsf 1st Floor	  	13,955 rsf 1st Floor
(includes 1,000 rsf)
	 Commencement Date 8/1/02
	  	$	36.00/rsf	  	 	—  	  	—  
				
	 Amendment Date 1/1/05-12/31/06
	  	$	36.00/rsf	  	$	15.00/rsf	  	—  
				
	 1/1/07-7/31/07
	  	$	36.00/rsf	  	 	—  	  	$18.80/rsf Base
 ($21,862.83/month)

				
	 1/1/07-7/31/07
	  	$	36.00/rsf	  	 	—  	  	$34.59/rsf Upfit
Amortized (a total of
$281,577.01 for the 7-month period)

 Renewal Term 
  

												
	 ONE TECH SPACE TERM
	  	SF	  	RENT	  	COMMENTS	 	TOTAL ANNUAL
(per
month)	 
	 1st Floor:
	  		  			  		 			
					
	 8/1/07-7/31/12
	  	13,955	  	$	18.80/rsf Base	  		 	$
 $
	262,354.00
 (21,862.83/mo
	  
 ) 

	 8/1/07-7/31/12
	  	13,955	  	$
 	34.59/rsf
Upfit Amortized	  	Upfit costs of $2.5
million @ 9% / 7 years	 	$	482,672.40	  
					
	 SUBTOTAL
	  		  			  		 	$	745,026.40	  
		  		  			  		 	 	 	 
	 3rd and 4th Floor:
 8/1/07-7/31/12
	  	40,432	  	$	33.60/rsf	  	Current rate is $36/sf
to 7/31/07	 	$
 $
	1,358,515.20
 (113,209.60
	  
 ) 

	 1st Floor:
 8/1/07-7/31/12
	  	2,969	  	$	18.80/rsf	  		 	$
 $
	55,817.20
 (4,651.43
	  
 ) 

	 SUBTOTAL
	  		  			  		 	$	1,414.332.40	  
		  		  			  		 	 	 	 
	 Basement Level:
 8/1/07-7/31/12
	  	704	  	$	10.00/rsf	  		 	$
 $
	7,040.00
 (586.67
	  
 ) 

					
	 SUBTOTAL
	  		  			  		 	$	7,040.00	  
		  		  			  		 	 	 	 
	 TOTAL:
	  		  			  		 	$	2,166,398.80	  
		  		  			  		 	 	 	 
	 Second Floor*
	  	20,669	  	 	20.00/rsf	  		 	$
 $
	413,380.00
 (34,448.33
	  
 ) 

  

	*	if corresponding Option to Lease is exercised by Tenant 

  

 2 

 Second Renewal Term 
 The annual rent per rentable square foot for all of the space leased during the Second Renewal Term, if any, shall be equal to the then-existing market rate for similar space in the Piedmont Triad in
North Carolina, as mutually determined in good faith by Landlord and Tenant. Unless Tenant does not have an interest in extending the term of the Lease for the Second Renewal Term, Landlord and Tenant shall exercise the requisite diligence to ensure
that they mutually determine the annual rent per rentable square foot applicable to the Second Renewal Term, in writing, on or before July 31, 2011. 
 The annual rent payable during the Initial Term, the Renewal Term, and, if applicable, the Second Renewal Term (herein collectively “Rent”) is payable in equal monthly installments in advance on
the first day of each calendar month of each calendar year during the Initial Term, the Renewal Term, and, if applicable, the Second Renewal Term, prorated for any partial month. Any increases or decreases in the amount of square footage leased
during a month will be adjusted in the subsequent monthly payment. Rent payments shall be payable to “Wake Forest University Health Sciences” and sent to Landlord in care of Controller’s Office, Attention: Doug Edgeton, Medical Center
Boulevard, Winston-Salem, NC 27157. 
 Except as amended herein, all the terms and conditions of the Lease remain in full force
and effect. 
 IN WITNESS WHEREOF, Landlord and Tenant have caused this Fourth Amendment to be executed, pursuant to authority
duly granted, effective as of August 1, 2007. 
  

									
	LANDLORD:	 		 	TENANT:
			
	Wake Forest University Health Sciences	 		 	Targacept, Inc.
					
	By:	 	 /s/ Douglas L. Edgeton
	 		 	By:	 	 /s/ J. Donald deBethizy

	Name:	 	Douglas L. Edgeton	 		 		 	J. Donald deBethizy
	Title	 	Exec. VP & COO	 		 		 	President
			
	Date: 9/18/07	 		 	Date: 9/14/07

  

 3 

 Exhibit A 
 Demised Premises 
 The Demised Premises consist of the following: 

 

	 	•	 	 As of the Commencement Date, all of the third and fourth floors, consisting of 40,432 rentable square feet, including within the meaning of
“Premises” or “Demised Premises” the entire fourth floor of the Building, to be utilized as Tenant’s laboratory facilities, encompassing 20,216 rentable square feet, and 20,216 rentable square feet of general office space on
the third floor; 

  

	 	•	 	 As of January 1, 2005, an additional 1,000 rentable square feet on the first floor of the Building, to be utilized as “Tenant’s Storage
Space”; 

  

	 	•	 	 As of January 1, 2007, additional space located on the first floor of the Building, consisting of 13,955 rentable square feet (inclusive of the
1,000 rentable square feet described above), as depicted on the attached First Level Floor Plan attached hereto as a part of Exhibit A-2: 

  

					
	 Rentable square footage*
	 	 Designation
 on
 Exhibit
A-2 First Floor Plan
	 	 Color
 of
 Designated Space on Plan

	6,555	 	Lab-1	 	blue
	2,293	 	Office-1	 	purple
	3,171	 	Office-2	 	olive
	1,936	 	Office-5	 	yellow

 ; and 

 

	 	•	 	 As of August 1, 2007, further additional space located on the first floor of the Building, consisting of 2,969 rentable square feet, as depicted
on the attached First Level Floor Plan attached hereto as a part of Exhibit A-2: 

  

					
	 Rentable square footage
	 	 Designation
 on
 Exhibit
A-2 First Floor Plan
	 	 Color
 of
 Designated Space on Plan

	741	 	Office-3	 	beige
	2,228	 	Office-4	 	salmon

  

	 	•	 	 As of August 1, 2007, additional space located on the ground floor of the Building, consisting of 704 rentable square feet, as depicted on the
attached Basement Level Floor Plan attached hereto as a part of Exhibit A-2; 

 ; in each case together with
rights of use of and subject to the rights of others in and to the Common Areas of the Building. Diagrams of the Demised Premises and Common Areas are as shown on the attached Exhibit A-2 (5 pages).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]